GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Yidu Tech Inc (HKSE:02158) » Definitions » Quality Rank

Yidu Tech (HKSE:02158) Quality Rank


View and export this data going back to 2021. Start your Free Trial

What is Yidu Tech Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Yidu Tech Quality Rank Related Terms

Thank you for viewing the detailed overview of Yidu Tech's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Yidu Tech (HKSE:02158) Business Description

Traded in Other Exchanges
Address
No.9 Building of Huayuan North Road, 8th Floor Health Work, Haidian District, Beijing, CHN
Yidu Tech offers healthcare Big Data. It is an AI cloud-based firm providing solutions and tools to aid in more informed decisions to drive better efficiency in clients' strategies. Its clients are hospitals, pharmaceutical, biotech and medical device firms, research institutions, insurance companies, patients, and regulators. It three business segments are: Big Data platform and solutions, which partners with hospitals and policymakers to drive better efficiency; life sciences solutions, which enables better probability of clinical trial success with less drug development time and cost; and health management solutions, which helps with patient management. The Big Data platform accounted for 33% of revenue, life science solutions 30%, and health management solutions 27%, in fiscal 2022.
Executives
Gong Yingying 2202 Interest of your spouse
Xu Jiming 2101 Beneficial owner
Brunei Investment Agency 2101 Beneficial owner
Gic Private Limited 2102 Investment manager
Sweet Panda Limited 2101 Beneficial owner